LENZ Therapeutics
LENZ
66 hedge funds and large institutions have $81.2M invested in LENZ Therapeutics in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 11 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
11% more capital invested
Capital invested by funds: $72.9M → $81.2M (+$8.38M)
6% more funds holding
Funds holding: 62 → 66 (+4)
0.38% more ownership
Funds ownership: 7.31% → 7.68% (+0.38%)
0% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $1.53M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.43M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.35M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$773K |
| 5 |
CA
CHI Advisors
New York
|
+$659K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$2.38M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$1.4M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.11M |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$914K |
| 5 |
Morgan Stanley
New York
|
-$378K |
LENZ Hedge Fund Activity: Q2 2023 in Review
66 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q2 2023, worth a combined $81.2M — up 11% from $72.9M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LENZ positions and 11 closed out — a net gain of 4 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $3.43M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $2.38M sold.
- 66 institutional investors held LENZ Therapeutics (LENZ) as of Q2 2023, up from 62 in Q1 2023.
- Funds reported $81.2M of LENZ Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
- 15 funds opened new LENZ Therapeutics positions in Q2 2023 and 11 closed out, a net change of +4 holders.
- The largest LENZ Therapeutics buyer in Q2 2023 was BlackRock, an estimated $3.43M added.
- The largest LENZ Therapeutics seller in Q2 2023 was K2 Principal Fund, an estimated $2.38M sold.
Based on aggregated 13F filings for Q2 2023.